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efﬁcacy and safety for diarrhea-predominant irritable bowel
syndrome (IBS-D). A phase 3, randomized, double-blind,
placebo-controlled trial was performed to evaluate the safety
and efﬁcacy of repeat treatment with the nonsystemic
antibiotic rifaximin. METHODS: The trial included adults with
IBS-D, mean abdominal pain and bloating scores of 3 or more,
and loose stool, located at 270 centers in the United States and
Europe from February 2012 through June 2014. Those
responding to a 2-week course of open-label rifaximin 550 mg
3 times daily, who then relapsed during an observation phase
(up to 18 weeks), were randomly assigned to groups given
repeat treatments of rifaximin 550 mg or placebo 3 times daily
for 2 weeks. The primary end point was percentage of re-
sponders after ﬁrst repeat treatment, deﬁned as a decrease in
abdominal pain of 30% from baseline and a decrease in fre-
quency of loose stools of 50% from baseline, for 2 or more
weeks during a 4-week post-treatment period. RESULTS: Of
1074 patients (44.1%) who responded to open-label rifaximin,
382 (35.6%) did not relapse and 692 (64.4%) did; of these, 636
were randomly assigned to receive repeat treatment with
rifaximin (n ¼ 328) or placebo (n ¼ 308). The percentage of
responders was signiﬁcantly greater with rifaximin than
placebo (38.1% vs 31.5%; P ¼ .03). The percentage of
responders for abdominal pain (50.6% vs 42.2%; P ¼ .018) was
signiﬁcantly greater with rifaximin than placebo, but not stool
consistency (51.8% vs 50.0%; P ¼ .42). Signiﬁcant improve-
ments were also noted for prevention of recurrence, durable
response, and bowel movement urgency. Adverse event rates
were low and similar between groups. CONCLUSIONS: In a
phase 3 study of patients with relapsing symptoms of IBS-D,
repeat rifaximin treatment was efﬁcacious and well tolerated.
ClinicalTrials.gov ID: NCT01543178.Abbreviations used in this paper: AE, adverse event; IBS-D,
diarrhea-predominant irritable bowel syndrome; TARGET, targeted,Keywords: Bloating; Functional Bowel Disease; Nonabsorbed;
Xifaxan.
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nonsystemic antibiotic rifaximin gut-selective evaluation of treatment for
IBS-D; TID, three times daily.
Most current article
© 2016 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
0016-5085
http://dx.doi.org/10.1053/j.gastro.2016.08.003D(IBS-D) is a common gastrointestinal disorder
characterized by recurring abdominal pain, bloating, and
loose stools in the absence of structural or biochemical
abnormalities.1 Nonpharmacologic options for the treatment
of IBS-D include psychological approaches, dietary
and lifestyle modiﬁcations, probiotics, and ﬁber supple-
mentation, although each has shown variable and lessthan optimal relief of IBS-D symptoms.2–4 Pharmacologic
therapies, such as anti-diarrheals (eg, loperamide),3 have
limited beneﬁcial effects on global IBS symptoms
(eg, abdominal pain), and the 5HT3 antagonist alosetron is
approved only for women with severe, treatment-refractory
IBS-D,3 with substantial restrictions on its use. Antidepres-
sants, such as tricyclic agents, although not approved for the
treatment of IBS-D, have been considered efﬁcacious for
reducing abdominal pain and global IBS symptoms in patients
with IBS.2 However, data on the efﬁcacy of these agents
speciﬁcally for treatment of IBS-D are limited.2 Eluxadoline,
a twice-daily m-opioid receptor agonist and d-opioid receptor
antagonist,5 was approved in 2015 for the treatment of IBS-D.
Patients with IBS have alterations in the intestinal
microbiota comparedwith healthy individuals6–14; therefore,
the intestinal microbiota may be an effective target for
treatment of IBS-D. Rifaximin is an oral, minimally absorbed,
broad-spectrum antimicrobial agent that targets the gastro-
intestinal tract and is associated with a low risk of clinically
relevant bacterial antibiotic resistance.15–18 Rifaximin was
approved by the US Food and Drug Administration in May
2015 for the treatment of IBS-D in adults. In 2 large, multi-
center, phase 3 trials of patients with IBS-D (Targeted,
Nonsystemic Antibiotic Rifaximin Gut-Selective Evaluation of
Treatment for IBS-D [TARGET] 1 and 2), 40.7% of patients
treatedwith rifaximin 550mg 3 times daily (TID) for 2 weeks
experienced adequate relief of global IBS symptoms for2 of
the ﬁrst 4 weeks post-treatment compared with 31.7% of
patients treated with placebo (D 9%; P < .001, pooled
data).15 In addition, a greater percentage of rifaximin-treated
than placebo-treated patients reported durable improve-
ment in IBS-D symptoms for at least 10weeks post-treatment
(P ¼ .001, pooled data). However, the persistence of this
treatment effect beyond the 10-week follow-up period,
assessed in TARGET 1 and 2, and the efﬁcacy and safety of
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symptom relapse, had only been evaluated in open-label,
retrospective studies.19,20
The aim of this trial, which included an open-label
enrichment phase followed by a randomized, placebo-
controlled phase, was to determine the efﬁcacy and safety
of repeat treatment with rifaximin in patients with IBS-D
who had responded to a 2-week course of rifaximin and
subsequently experienced IBS symptom recurrence. Specif-
ically, the primary efﬁcacy assessment compared the
percentage of patients who were repeat responders for both
abdominal pain and stool consistency during the ﬁrst 4
weeks after a second course of treatment (repeat treatment
with rifaximin or treatment with placebo).
Methods
Study Patients
Eligible patients were 18 years of age or older; had a
colonoscopy in the past 10 years or underwent a ﬂexible
sigmoidoscopy with biopsies; received a diagnosis of IBS
(conﬁrmed by Rome III diagnostic criteria); and did not have
adequate relief of global IBS symptoms and bloating during a
screening phase. Exclusion criteria included renal or hepatic
disease, diabetes, and history of inﬂammatory bowel disease;
previous gastrointestinal surgery; abnormal thyroid function
not adequately controlled by thyroid medication; and infection
with human immunodeﬁciency virus or hepatitis B or C.
Based on daily responses to a diary questionnaire
(Supplementary Table 1) during the placebo-screening phase,
patients must have rated their average abdominal pain 3
(scale 0–10: 0 ¼ no pain; 10 ¼ worst possible pain) and
bloating 3 (scale 0–6: 0 ¼ not at all; 6¼ a very great deal) and
have experienced loose stools for 2 days in a week with a
Bristol Stool Scale type 6 (ﬂuffy pieces with ragged edges, a
mushy stool) or 7 (watery stool, no solid pieces; entirely liquid
stool). These 3 inclusion criteria had to be met for patients to
proceed in the study. Furthermore, patients were excluded if
(after initiating diary assessments during the placebo-screening
phase) they were taking anti-diarrheals, anti-spasmodics,
narcotics, prokinetic drugs, warfarin, drugs indicated for IBS
(eg, alosetron, lubiprostone), or products marketed as
probiotics; patients also were excluded if they were taking
rifaximin or any antibiotic within 14 days before providing
written informed consent. Patients could continue to take
antidepressant agents, provided that they had been taking a
stable dose for at least 6 weeks before providing written
informed consent. The protocol was approved by all institu-
tional review boards and ethics committees at participating
sites, and all patients provided written informed consent. All
authors had full access to the study data and reviewed and
approved the ﬁnal manuscript.
Study Design
In total, 270 centers in the United States, Germany, and the
United Kingdom participated in the randomized, double-blind,
placebo-controlled, 51-week, phase 3 trial (Figure 1A)
conducted from February 2012 through June 2014
(ClinicalTrials.gov ID: NCT01543178). After a prescreening
eligibility phase, patients entered into a single-blind screening(ie, baseline) phase of placebo TID for 10 ± 3 days. After
completion of the screening phase, patientsmeeting all eligibility
criteria entered into the open-label treatment phase, which
consisted of open-label treatment with rifaximin 550 mg TID for
2 weeks, followed by a 4-week assessment period to determine
response to rifaximin. A responder was deﬁned as a patient
simultaneously meeting weekly response criteria for abdominal
pain (30% decrease from baseline in mean weekly pain score)
and stool consistency (50% decrease from baseline in number
of days/weekwithBristol Stool Scale type 6 or 7 stool) during2
of the 4 weeks after treatment. Responders to open-label
rifaximin were then monitored in an observation phase for up
to an additional 18 weeks or until symptom relapse occurred.
Patients who failed to meet the prespeciﬁed weekly response
criteria for both abdominal pain and stool consistency after the
initial open-label rifaximin treatment were classiﬁed as
nonresponders and withdrawn from the trial.
Patients who were classiﬁed as responders to the initial
open-label rifaximin treatment and who experienced a relapse
in IBS-D symptoms (deﬁned as a loss of treatment response for
either weekly abdominal pain [<30% decrease from baseline in
mean weekly pain score] or stool consistency [<50% decrease
from baseline in number of days/week with Bristol Stool Scale
type 6 or 7 stool] for 3 weeks of a consecutive, rolling 4-week
period during the 18-week observation phase) entered into the
double-blind treatment phase of the trial, in which patients
were randomly assigned (1:1) to receive 2 repeat treatment
courses of rifaximin 550 mg TID or placebo TID for 14 days.
Randomization was stratiﬁed by site. Each site used a
randomization code generated and maintained by a clinical
research organization by a block randomization schema (block
size of 2) using a computerized interactive voice or web
response system that was independent of other centers’
randomization codes. Response to repeat treatment was
assessed during the 4 weeks immediately after a repeat treat-
ment course. The prespeciﬁed primary evaluation period for
the trial was the 4-week follow-up period after the ﬁrst repeat
treatment. However, all patients, regardless of response or
relapse status after the ﬁrst repeat treatment, received a
second repeat treatment with the same treatment assigned at
randomization (ie, rifaximin 550 mg or placebo TID for 14
days). The second repeat treatment course was initiated 10
weeks after completion of the ﬁrst repeat treatment course
(ie, after the 4-week primary evaluation period and 6-week
repeat treatment observation phase) and was included to
assess the safety of additional treatment with rifaximin. The
overall trial design reﬂected input from the United States and
European health authorities, and is in keeping with the
subsequent publication of US Food and Drug Administration
and European Medicines Agency guidance for the development
of drugs for IBS.21–23
Efﬁcacy End Points and Safety Assessments
An interactive voice or web response system was used to
collect responses to daily symptom questions and a separate
weekly global IBS symptom question (Supplementary Table 1).
The primary end point of the trial was the percentage of
patients who were responders (as deﬁned here) for both
abdominal pain and stool consistency during the 4-week
follow-up after the ﬁrst repeat treatment course (see
Figure 1A). Three key secondary end points were evaluated:
Figure 1. Study design (A) and mean baseline IBS symptom severity for patients entering the open-label treatment phase
versus the same patients entering the double-blind, ﬁrst repeat treatment phase (n ¼ 636) (B). DB, double-blind; EOS, end of
study; IBS, irritable bowel syndrome; OL, open-label; SC, stool sample collection time point.
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did not have recurrence through the end of the 6-week
repeat treatment observation phase and continued to
respond without recurrence through the end of the
second repeat treatment phase;
2. Sustained IBS symptom relief (“durable” response): per-
centage of responderswho did not have recurrence through
the 6-week repeat treatment observation phase; and
3. Bloating response: percentage of patients with 1-point
decrease from baseline in weekly average bloating score
for 2 weeks during the 4-week primary evaluation
period.Additional efﬁcacy assessments included bowel movement
urgency and daily global IBS symptoms (all; Supplementary
Table 1). Bowel movement urgency response was deﬁned as
30% improvement from baseline in the percentage of days
with urgency for 2 weeks during the 4-week primary eval-
uation period. Safety assessments included monitoring of
adverse events (AEs), clinical laboratory tests, and vital sign
measurements. Stool samples were collected before and after
open-label rifaximin, before and after the ﬁrst double-blind
repeat treatment, and at study end. In order to receive
open-label rifaximin, patients were required to test negative
for Clostridium difﬁcile toxins A and B via enzyme
immunoassay.
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Sample size was estimated assuming that 40% and 55% of
patients in the placebo and rifaximin groups, respectively
(15% treatment difference), would achieve the primary end
point criteria (weekly response for abdominal pain and stool
consistency during at least 2 of the 4 weeks) during the primary
evaluation period with a signiﬁcance level of 5% (a¼ .05). With
these assumptions, a sample size of 300 patients in
each treatment group would provide 90% power to detect
statistically signiﬁcant treatment differences. All analyses were
stratiﬁed by analysis center.
Missing data were handled using the “worst-case” analysis
methodology for the primary end point and key secondary end
points. Individual patient responses from daily diary questions
were summarized into aweekly value for which at least 4 days of
data were recorded within a week; patients who reported <4
days of diary data in a given week were considered
nonresponders for that week, regardless of the data collected for
that week. The primary analysis using worst-case methodology
employed the Cochran–Mantel–Haenszel method, adjusting for
analysis center and time to recurrence. A sensitivity analysis
using multiple imputation for the primary efﬁcacy end point was
also conducted, using the Markov Chain Monte Carlo method,
adjusting for analysis center, time to recurrence, and recurrence
type. Other efﬁcacy end point analyses were conducted using
last observation carried forward. Binary data were analyzed
using the Cochran–Mantel–Haenszel method. Durable response
was analyzed by the Smirnov test. Time to recurrence was
determined by the Kaplan–Meier method and analyzed by
log-rank test. Symptom severity reported during theweek before
entry into the double-blind phase (ﬁrst repeat treatment phase)
was used as the baseline for assessing response to treatment.
Change from baseline in continuous outcomes was analyzed
using ﬁxed-effects linear models with ﬁxed effects for study arm,
analysis center, and baseline value as covariates.
The safety population was the same as the intent-to-treat
population. Safety was evaluated for the open-label treatment
phase (2-week open-label rifaximin, 4-week follow-up, and up
to 18 weeks of observation); while on treatment during the
double-blind treatment phase (ﬁrst 2-week repeat treatment
and second 2-week repeat treatment); and overall during the
double-blind treatment, observation, and follow-up (entire
double-blind treatment phase and ﬁnal 4-week follow-up
phase). Analyses were performed using SAS, version 9.3 (SAS
Institute, Cary, NC).Results
Open-label Treatment Phase
Among the 2579 patients with IBS-D who received
open-label rifaximin 550 mg TID, 2438 were evaluable for
efﬁcacy. Of these patients, 1074 (44.1%) experienced
improvement in both abdominal pain and stool consistency
on the same weeks for 2 of 4 weeks after treatment and
were considered responders and entered the observation
phase (up to 18 weeks; see Supplementary Figure 1). In an
individual assessment of these 2 symptom components,
56.8% of the 2438 patients were classiﬁed as abdominal
pain responders and 60.1% were classiﬁed as stool
consistency responders. During the observation phase, 692(64.4%) patients experienced symptom relapse, and 636 of
these patients (median time to symptom recurrence, 10.0
weeks) were randomized to double-blind repeat treatment.
However, 382 patients (35.6%) did not experience relapse
during the 18-week observation phase before being
withdrawn from the trial for any reason and did not proceed
to double-blind repeat treatment.
The demographics and baseline characteristics of the 636
randomized patients were similar between treatment groups
and similar to the overall population entering the initial open-
label phase and the population not continuing into the
double-blind phase (Table 1). However, baseline symptom
scores were signiﬁcantly lower at the time of randomization
than those reported before entering the initial open-label
treatment phase (P < .001 for all; paired t test) (Figure 1B).
For example, at the time of randomization, patients were
experiencing, on average, a 20% improvement in abdominal
pain (ie, less severe abdominal pain) relative to their symp-
tom severity before open-label rifaximin.
Double-Blind Repeat Treatment Phase
Upon repeat treatment, 38.1% of rifaximin-treated
patients were primary end point responders, compared
with 31.5% of placebo-treated patients using the worst-case
analysis for missing data (D 7%; P¼ .03; Table 2). A multiple
imputation sensitivity analysis for missing data resulted in a
similar treatment difference (D 8%) with rifaximin (40.2%)
vs placebo (32.4%; P ¼ .01; 95% conﬁdence interval, 0.4%–
15.3%). For the individual components of the primary efﬁ-
cacy end point, a signiﬁcantly greater percentage of patients
retreated with rifaximin vs placebo were responders for
abdominal pain (50.6% vs 42.2% with placebo; D 9%; P ¼
.018), but not stool consistency (51.8% vs 50.0% with pla-
cebo; D 2%; P ¼ .42). For the 3 key secondary end points, a
signiﬁcantly greater percentage of rifaximin-retreated pa-
tients were responders for IBS prevention of recurrence and
sustained IBS symptom relief (durable response) relative to
placebo-treated patients (Table 2). No signiﬁcant group
difference in the percentage of responders for bloating was
detected using the worst-case analysis for missing data
(Table 2). A greater percentage of rifaximin-treated patients
were responders for bowel movement urgency compared
with placebo-treated patients (48.5% vs 39.6%, respectively;
D 9%; P ¼ .03 [last observation carried forward]). Mean
changes over time for IBS symptoms (ie, abdominal pain,
stool consistency, bloating, stool frequency, and bowel
movement urgency) improved after the ﬁrst rifaximin repeat
treatment and improved again after the second rifaximin
repeat treatment, when compared with placebo (see Figure 2
for abdominal pain and Supplementary Figures 2–6 for other
symptoms).
Safety
In patients who entered the repeat treatment phase, AEs
were reported in 140 (42.7%) and 140 (45.5%) patients
taking rifaximin vs placebo, respectively (Table 3). AEs
considered by investigators to be related to study drug were
experienced by 6 (1.8%) and 8 (2.6%) patients in the
Table 1.Patient Demographic and Baseline Characteristics at Enrollmenta
Characteristic
Open-label population Double-blind population
Rifaximin, 550 mg
TID (n ¼ 2579)
Non–double-blind
population (n ¼ 1943)
Rifaximin, 550 mg
TID (n ¼ 328)
Placebo
(n ¼ 308)
Age, y, mean (SD) 46.4 (13.7) 46.3 (13.5) 47.9 (14.2) 45.6 (13.8)
Sex, n (%)
Male 819 (31.8) 624 (32.1) 106 (32.3) 89 (28.9)
Female 1760 (68.2) 1319 (67.9) 222 (67.7) 219 (71.1)
Race, n (%)
White 2155 (83.6) 1620 (83.4) 273 (83.2) 262 (85.1)
Black 289 (11.2) 221 (11.4) 37 (11.3) 31 (10.1)
Other 135 (5.2) 102 (5.2) 18 (5.5) 15 (4.9)
Duration since ﬁrst onset of
IBS symptoms, y, mean (SD)
10.9 (10.8) 10.8 (10.8) 11.4 (11.0) 11.2 (10.9)
Average daily scores, mean (SD)
Abdominal pain 5.5 (1.7) 5.5 (1.7) 5.7 (1.7) 5.5 (1.6)
Stool consistency 5.6 (0.8) 5.6 (0.9) 5.6 (0.8) 5.6 (0.8)
Bloating 4.1 (0.9) 4.1 (0.9) 4.2 (0.9) 4.1 (0.9)
IBS symptoms 4.2 (0.9) 4.1 (0.9) 4.2 (0.9) 4.1 (0.9)
No. of daily bowel movements,
mean (SD)
3.9 (2.2) 3.9 (2.2) 3.8 (2.1) 3.7 (2.1)
Days with BSS type 6 or 7 stool
in a week, mean (SD)
4.9 (1.8) 4.9 (1.9) 4.9 (1.8) 5.0 (1.7)
Days with bowel movement
urgency in a week, mean (SD)
5.9 (1.7) 5.9 (1.7) 5.9 (1.7) 5.8 (1.7)
Country
United States 2567 (99.5) 1931 (99.4) 328 (100) 308 (100)
United Kingdom 12 (0.5) 12 (0.6) 0 0
BSS, Bristol Stool Scale.
aSafety population and intent-to-treat population during double-blind repeat treatment phases were the same.
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resulting in study discontinuation during the double-blind
phases of the study were rare for the 636 patients, occur-
ring in just 1 patient (0.3%) in each treatment group. The
most commonly reported AEs occurred with similarTable 2.Primary and Key Secondary End Points
Assessment
Re
Rifaximin, 550 mg
Primary end point
Abdominal pain and stool consistencya,b 125/328 (3
Key secondary end points
Prevention of recurrenceb,c 39/295 (1
Durable responseb,d 56/328 (1
Bloatingb,e 153/328 (4
aPercentage of responders to repeat treatment with rifaximin,
consistency during 2 weeks of the 4-week primary evaluation
bMissing data analyzed using worst-case analysis methodology
cAnalysis in population that received a second repeat treatmen
both abdominal pain and stool consistency during the 4-week pr
treatment-free repeat treatment observation phase and the sec
dSustained IBSsymptomrelief (ie,durable response)wasdeﬁnedasad
4-week primary evaluation period, with no recurrence through the 6-w
ePercentage of patients with a 1-point decrease from baselin
4-week primary evaluation period.frequency in each treatment group (Table 3). Constipation
was only reported in 1 (0.3%) patient in the rifaximin group
and 3 (1.0%) patients in the placebo group. The proﬁle and
incidence of AEs in the double-blind phase was comparable
with that reported during the open-label phase. When AEssponders, n/total (%)
P value (95% CI)TID (n ¼ 328) Placebo (n ¼ 308)
8.1) 97/308 (31.5) .03 (0.9 to 16.9)
3.2) 20/283 (7.1) .007 (2.5 to 20.0)
7.1) 36/308 (11.7) .04 (1.4 to 16.6)
6.6) 127/308 (41.2) .14 (0.9 to 15.0)
deﬁned as improvement in both abdominal pain and stool
period (ie, primary end point).
.
t. Prevention of recurrence was deﬁned as adequate relief in
imary evaluation period, with no recurrence during the 6-week
ond 6-week repeat treatment phase.
equate relief inbothabdominalpainandstoolconsistencyduring the
eek treatment-free repeat treatment observation phase.
e in weekly average bloating score for 2 weeks during the
Figure 2. Change from
baseline in average daily
abdominal pain scores
during the ﬁrst and second
repeat treatment double-
blind phases. aStatistically
signiﬁcant difference vs
placebo. Data were
analyzed using last obser-
vation carried forward
methodology.
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phase (during ﬁrst and second 2-week repeat treatments),
the most commonly reported AEs for rifaximin vs placebo
were increased alanine aminotransferase levels (2.1% vs
1.0%) and nausea (1.8% vs 1.3%) (Supplementary Table 2).
During the double-blind phase, serious AEs were reportedTable 3.Summary of Adverse Events During Open-label (n ¼ 2
AE, n (%)
Open-label populat
Rifaximin, 550 mg
TID (n ¼ 2579)
Any AE 822 (31.9)
Drug-related AE 85 (3.3)
Serious AE 28 (1.1)
Most common AEsd
Nausea 52 (2.0)
Upper respiratory tract infection 41 (1.6)
Urinary tract infection 35 (1.4)
Nasopharyngitis 36 (1.4)
Alanine aminotransferase increased 24 (0.9)
Blood creatinine phosphokinase increased 31 (1.2)
Bronchitis 15 (0.6)
Aspartate aminotransferase increased 24 (0.9)
Diarrhea 20 (0.8)
Inﬂuenza 33 (1.3)
Sinusitis 34 (1.3)
Headache 42 (1.6)
Arthralgia 17 (0.7)
aDuring double-blind phase, AEs were assessed during the ﬁrs
repeat treatment observation phase, the second 6-week repeat
bFour patients experienced serious adverse events: fall (n¼ 1),Clos
(n¼1); noneof thesewereconsideredby investigators tobe related
cFour patients experienced serious adverse events: severe ce
coronary artery occlusion (n ¼ 1), moderate transient ischemic
ischemic attack (n ¼ 1); none of these were considered by inve
d2.0% of patients in either treatment group and ordered by mfor 4 patients in each treatment group, and none of these
were considered by investigators to be related to treatment.
One patient developed C difﬁcile colitis infection 37 days
after rifaximin repeat treatment. This patient tested
negative for C difﬁcile toxins A and B at study entry, had a
medical history of C difﬁcile infection, and had completed a579) and Double-blind (n ¼ 636) Phasesa
ion Double-blind population
Rifaximin 550 mg TID (n ¼ 328) Placebo (n ¼ 308)
140 (42.7) 140 (45.5)
6 (1.8) 8 (2.6)
4 (1.2)b 4 (1.3)c
12 (3.7) 7 (2.3)
12 (3.7) 8 (2.6)
11 (3.4) 15 (4.9)
10 (3.0) 9 (2.9)
9 (2.7) 4 (1.3)
9 (2.7) 3 (1.0)
9 (2.7) 5 (1.6)
7 (2.1) 4 (1.3)
7 (2.1) 3 (1.0)
7 (2.1) 2 (0.6)
7 (2.1) 7 (2.3)
4 (1.2) 9 (2.9)
3 (0.9) 8 (2.6)
t 6-week repeat treatment phase, the 6-week treatment-free
treatment phase, and the ﬁnal 4-week follow-up phase.
tridiumdifﬁcile colitis (n¼ 1), dyspnea (n¼ 1), and breast cancer
tostudydrug.All eventswereclassiﬁedasmoderate in intensity.
llulitis (n ¼ 1), moderate noncardiac chest pain and severe
attack (n ¼ 1), and severe hypertension and severe transient
stigators to be related to study drug.
ost common AE in double-blind rifaximin group.
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immediately before development of C difﬁcile colitis. No
events of increased alanine aminotransferase levels during
repeat treatment (Supplementary Table 2) were considered
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Previous trials of rifaximin (TARGET 1 and TARGET 2)
have demonstrated that a single 2-week course of therapy
improves IBS-D symptoms, such as abdominal pain.15 While
retrospective chart reviews suggest that repeat treatment
with rifaximin is safe and effective in patients with recur-
rent symptoms,19,20 the durability of effect and efﬁcacy and
safety of repeat treatment had not been systematically
evaluated. In this randomized, controlled trial, rifaximin-
treated patients who responded to an initial, open-label,
2-week course of rifaximin and then relapsed during
follow-up (up to 18 weeks) were signiﬁcantly more likely to
respond to repeat treatment with rifaximin compared with
placebo (38.1% vs 31.5%; P ¼ .03). Importantly, 35.6% of
patients did not experience IBS-D symptom relapse for up to
18 weeks of follow-up after responding to the initial,
open-label course of rifaximin.
Although the percentage of composite primary end point
(abdominal pain and stool consistency) responders was
signiﬁcantly higher with repeat treatment with rifaximin vs
placebo, an evaluation of the individual end point compo-
nents found a statistically signiﬁcant difference for abdom-
inal pain responders, but not stool consistency responders
vs placebo. Likewise, unlike the previous phase 3 trials that
reported a signiﬁcantly higher percentage of patients with
weekly improvement in bloating (rifaximin [40.2%] vs
placebo [30.3%; P < .001, pooled data]),15 there was no
statistically signiﬁcant difference with regard to bloating
observed with repeat treatment with rifaximin vs placebo in
the current study.
Consistent with previous trials of rifaximin for
IBS,15,24–26 this agent was well tolerated in the current
trial, and the number of overall and serious AEs was
similar, apart from nausea, in the rifaximin and placebo
groups.18 Furthermore, the incidence of constipation
adverse events during treatment with rifaximin was
similar to that for placebo, possibly consistent with a lack
of effect of rifaximin on gut motility. Importantly, repeat
treatment with rifaximin did not result in an increase
in the incidence of AEs. One case of clinical C difﬁcile
infection was reported in the current trial.
Patients with IBS have been shown to have alterations in
gut microbiota compared with healthy controls,6–14 with
several of these studies pointing to the possibility of alter-
ations in the small intestinal microbiota. Using quantitative
polymerase chain reaction, patients with IBS-D have been
shown to have increased numbers of duodenal coliform
bacteria.14 There is growing evidence that gut microbes can
inﬂuence intestinal motility, epithelial integrity, bile acid
metabolism, and the brain–gut axis communication, thusplaying an important role in human health and disease.27,28
Alterations in the gut microbiota may impact one or more of
these gastrointestinal tract activities, and potentially result
in IBS symptoms.
Rifaximin is a rifamycin derivative with minimal
absorption, which may account, in part, for the tolerability
proﬁle observed in this andprior studies. In addition to IBS-D,
rifaximin is approved by the US Food and Drug Administra-
tion for the treatment of traveler’s diarrhea and reduction in
risk of hepatic encephalopathy recurrence. In 2 large, ran-
domized, double-blind, placebo-controlled trials (TARGET 1
and 2), a single, 2-week course of rifaximin demonstrated
efﬁcacy compared with placebo, as assessed during a 4-week
treatment-free follow-up period.15 In addition, in these trials,
many rifaximin-treated patients continued to experience
beneﬁt for a follow-up period of 10 weeks.
In the current trial, more than one-third of patients who
responded to open-label rifaximin did not experience a
relapse of IBS-D symptoms when followed for up to 18
weeks after treatment response. Given that the primary aim
of the current trial was to assess the effects of repeat
treatment with rifaximin, patients who did not experience
loss of response to open-label rifaximin during this period
were withdrawn from the trial. Therefore, the duration of
efﬁcacy after a single course of rifaximin is unknown in this
subgroup of patients. An additional limitation of the study is
that it can be difﬁcult to detect rare adverse events with
clinical trials of this population size. Furthermore, the study
was restricted to a maximum of 3 treatment courses of
rifaximin. Given that many patients may require long-term
(eg, years) management of IBS-D symptoms, the potential
risk-to-beneﬁt proﬁle of periodic administration of a
nonsystemic antibiotic after 3 treatment courses is unclear.
The design of the current trial has several aspects
worthy of discussion. A potential explanation for the rela-
tively small delta (wD 7%) observed after repeat treatment
with rifaximin or placebo is that patients who had recurrent
IBS symptoms after responding to open-label rifaximin
reported that the severity of these symptoms was sub-
stantially lower than at open-label baseline. The lesser
severity of symptoms at the onset of the ﬁrst double-blind,
repeat treatment phase may reduce the statistical power to
detect measurable improvement in symptoms due to a
“ﬂoor effect.”29 Additionally, this ﬂoor effect may have
theoretically impacted the ability to detect a statistically
signiﬁcant difference in responders for the individual IBS
symptoms of abdominal pain and stool consistency that
comprised the primary end point. Despite this, repeat
treatment with rifaximin provided improvements beyond
the continued symptom improvement achieved with the
initial open-label treatment. The second repeat treatment
with rifaximin or placebo was given to patients 10 weeks
after the ﬁrst repeat treatment, irrespective of recurrence of
IBS symptoms, because the primary purpose of the second
repeat treatment was to gain additional data on safety and
tolerability associated with rifaximin retreatment rather
than efﬁcacy. Finally, the deﬁnition of relapse, which stipu-
lated that patients could experience recurrent symptoms for
abdominal pain or stool consistency or both, created a
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ATdegree of heterogeneity in the patients who were random-
ized. Nevertheless, this design is analogous to common
clinical practice and provides information relevant for
determining when repeat treatment may be appropriate.
There may be concern that a 7% gain over placebo in
improvement of abdominal pain and stool consistency
(primary end point) does not indicate a substantial clinical
impact. One could hypothesize that the current study design
may have played at least some role in this observation.
Patients who responded to rifaximin with no observed
relapse during the 18-week treatment-free follow-up period
did not proceed into the randomized, double-blind phase.
Thus, only patients with symptom recurrence were treated
with rifaximin or placebo as repeat treatment. In essence,
the trial indicated that patients with a lower effect with
rifaximin (ie, relapse) responded to a repeat course of
treatment. Thus, to succeed in TARGET 3, patients had to
achieve criteria for response for a composite end point
(abdominal pain and stool consistency) with open-label
rifaximin; relapse within a set period of time; and achieve
criteria for the composite end point again, in a double-blind
fashion, when treatment was repeated. Furthermore, as
noted previously, symptom severity at double-blind base-
line was reduced compared with open-label baseline, indi-
cating a potential residual beneﬁt of rifaximin in patients
who experienced relapse after response to an initial open-
label course of the drug. Finally, because this is not a pri-
mary efﬁcacy trial, it would not be appropriate to calculate a
number needed to treat using the data from this study.
Pooled analyses of randomized, placebo-controlled trials
have reported the number needed to treat of rifaximin to
range from 10.2 to 10.6.30,31
This prospective, randomized, placebo-controlled trial
demonstrates that repeat treatment (up to 3 courses) with
rifaximin 550 mg TID for 2 weeks in patients with recurrent
IBS-D symptoms confers signiﬁcant clinical improvement
during a treatment-free follow-up period. Although this
study had a positive outcome, questions remain about the
role of nonsystemic antibiotics in the long term, particularly
when patients with IBS-D may require years of symptom
management. Further research is needed to better under-
stand the treatment algorithm in patients who may lose
responsiveness to rifaximin.Supplementary Material
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